Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fncel.2017.00246 http://scihub22266oqcxt.onion/10.3389/fncel.2017.00246 C5572234!5572234!28878622     free     free     free       Front+Cell+Neurosci 2017 ; 11 (ä): ä Nephropedia Template TP {{tp|p=28878622|t=2017. Ganaxolone: A New Treatment for Neonatal Seizures |pdf=|usr=}}{{28878622}} gab.com Text Ganaxolone: A New Treatment for Neonatal Seizures JO: Front Cell Neurosci http://www.kidney.de/pget.php?&tw=1&pmid=28878622 #FOAvip Neonatal seizures are amongst the most common neurologic conditions managed by a neonatal care service. Seizures can exacerbate existing brain injury, induce ?de novo? injury, and are associated with neurodevelopmental disabilities in post-neonatal life. In this mini-review, we present evidence in support of the use of ganaxolone, a GABAA agonist neurosteroid, as a novel neonatal therapy. We discuss evidence that ganaxolone can provide both seizure control and neuroprotection with a high safety profile when administered early following birth-related hypoxia, and show evidence that it is likely to prevent or reduce the incidence of the enduring disabilities associated with preterm birth, cerebral palsy, and epilepsy. We suggest that ganaxolone is an ideal anti-seizure treatment because it can be safely used prospectively, with minimal or no adverse effects on the neonatal brain. Twit Text FOAVip Ganaxolone: A New Treatment for Neonatal Seizures ????Front Cell Neurosci http://www.kidney.de/pget.php?&tw=1&pmid=28878622 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28878622 #FOAvip English Wikipedia <ref>{{Cite pmid|28878622}}</ref> Ganaxolone: A New Treatment for Neonatal Seizures #MMPMID28878622 Yawno T; Miller SL; Bennet L; Wong F; Hirst JJ; Fahey M; Walker DW Front Cell Neurosci 2017[]; 11 (ä): ä PMID28878622show ga Neonatal seizures are amongst the most common neurologic conditions managed by a neonatal care service. Seizures can exacerbate existing brain injury, induce ?de novo? injury, and are associated with neurodevelopmental disabilities in post-neonatal life. In this mini-review, we present evidence in support of the use of ganaxolone, a GABAA agonist neurosteroid, as a novel neonatal therapy. We discuss evidence that ganaxolone can provide both seizure control and neuroprotection with a high safety profile when administered early following birth-related hypoxia, and show evidence that it is likely to prevent or reduce the incidence of the enduring disabilities associated with preterm birth, cerebral palsy, and epilepsy. We suggest that ganaxolone is an ideal anti-seizure treatment because it can be safely used prospectively, with minimal or no adverse effects on the neonatal brain. äGanaxolone: A New Treatment for Neonatal Seizures (epmc).pdf DeepDyve Pubget Overpricing